Non‐small‐cell lung cancer with ERBB2 mutation in non‐tyrosine kinase domain benefits from pyrotinib: A case report

Tyrosine kinase domain (TKD) mutation and particularly exon 20 insertion mutations of erb‐b2 receptor tyrosine kinase 2 (ERBB2/HER2) have been extensively reported in non‐small cell lung cancer (NSCLC). Nevertheless, the clinical significance of non‐TKD mutations remains unknown. To date, no clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Jun, Si, Xiao‐yan, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046093/
https://www.ncbi.nlm.nih.gov/pubmed/33655632
http://dx.doi.org/10.1111/1759-7714.13889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046093/
https://www.ncbi.nlm.nih.gov/pubmed/33655632
http://dx.doi.org/10.1111/1759-7714.13889

Ejemplares similares